Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $7.40 USD
Change Today -0.20 / -2.63%
Volume 193.2K
ONCS On Other Exchanges
Symbol
Exchange
NASDAQ CM
Berlin
As of 8:10 PM 06/1/15 All times are local (Market data is delayed by at least 15 minutes).

oncosec medical inc (ONCS) Key Developments

OncoSec Medical and Massachusetts General Hospital to Evaluate Efficacy of Intratumoral Delivery of DNA-Based Interleukin-12

OncoSec Medical Inc. announced it has entered a Sponsored Research Agreement (SRA) with Massachusetts General Hospital. Under the agreement, researchers will evaluate the immunologic mechanisms underlying the anti-tumor effects of OncoSec's clinical stage platform, ImmunoPulseTM IL-12, in a Human Papilloma Virus (HPV) tumor mouse model. HPV-associated tumors include oropharyngeal and certain genitourinary cancers (e.g., cervical cancer). OncoSec's immunotherapy platform, ImmunoPulseTM IL-12, is designed to deliver and enhance the uptake of DNA-based IL-12 directly into tumors. OncoSec is currently conducting Phase II clinical trials of ImmunoPulseTM IL-12 in metastatic melanoma and plans to initiate Phase II studies in head and neck cancer and triple negative breast cancer. Preliminary data from melanoma clinical trials show evidence that ImmunoPulseTM IL-12 can generate a local immune response as well as systemic anti-tumor effects. IL-12 is an inflammatory cytokine that regulates multiple aspects of the immune system and initiates both innate and adaptive immune responses. IL-12 is a key driver of the cascade of biological events that ultimately lead to T-cell-specific killing of cancer cells. Moreover, cytokines and chemokines induced by this pathway also increase the recruitment of inflammatory T-cells into tumors.

OncoSec Medical Incorporated will Change its Ticker to ONCS.D from ONCS

Effective May 18, 2015, OncoSec Medical Incorporated will change its Pink Sheets LLC stock ticker symbol to ONCS.D from ONCS.

OncoSec Medical Incorporated Presents at Sachs Immuno-Oncology: BD&L and Investment Forum, May-29-2015 04:30 PM

OncoSec Medical Incorporated Presents at Sachs Immuno-Oncology: BD&L and Investment Forum, May-29-2015 04:30 PM. Venue: Hyatt Chicago Magnificent Mile, Chicago, Illinois, United States. Speakers: Punit S. Dhillon, Co-Founder, Chief Executive Officer, President and Director.

OncoSec Medical Incorporated Presents at Needham & Company's 14th Annual Healthcare Conference, Apr-14-2015 08:40 AM

OncoSec Medical Incorporated Presents at Needham & Company's 14th Annual Healthcare Conference, Apr-14-2015 08:40 AM. Venue: Westin Grand Central Hotel, New York, New York, United States. Speakers: Punit S. Dhillon, Co-Founder, Chief Executive Officer, President and Director.

OncoSec Medical Incorporated Announces Earnings Results for the Six Months Ended January 31, 2015

OncoSec Medical Incorporated announced earnings results for the six months ended January 31, 2015. For the period, the company reported net loss of $8.7 million, or $0.04 per share, compared to a net loss of $4.7 million, or $0.03 per share, for the same period last year. There were no revenues for the six months ended January 31, 2015 or January 31, 2014.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ONCS:US $7.40 USD -0.20

ONCS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ONCS.
View Industry Companies
 

Industry Analysis

ONCS

Industry Average

Valuation ONCS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 3.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ONCOSEC MEDICAL INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.